Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Galina V. Seledtsova

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Oncotarget|December 6, 2018
Attaining threshold antibody cytotoxicity for selective tumor cell destruction: an opinion articleVictor I Seledtsov, Galina V Seledtsova
Frontiers in Immunology|April 22, 2017
A Possible Role for Idiotype/Anti-idiotype B-T Cell Interactions in Maintaining Immune MemoryVictor I Seledtsov, Galina V Seledtsova
Expert Review of Clinical Immunology|May 11, 2019
Total threshold cytotoxicity of therapeutic antibodies for selective destruction of pathogenic memory T cells: implications for immunotherapy of autoimmune and allergenic disordersVictor I Seledtsov, Galina V Seledtsova
International Journal of Molecular Sciences|August 28, 2025
Low Antibody Dosing in Cancer Therapy: Targeted Cytotoxicity Combined with Anti-Tumour ImmunostimulationVictor I Seledtsov, Galina V Seledtsova, Adas Darinskas, et al.
Journal of Immunotoxicology|September 8, 2016
Immune responses to polyclonal T-cell vaccination in patients with progressive multiple sclerosisGalina V Seledtsova, Irina P Ivanova, Alexey A Shishkov, et al.
Human Vaccines & Immunotherapeutics|May 8, 2019
Directs effects of granulocyte-macrophage colony stimulating factor (GM-CSF) on adaptive immunogenesisVictor Ivanovich Seledtsov, Vladimir V Malashchenko, Natalja D Gazatova, et al.
European Journal of Dermatology : EJD|March 31, 2016
Xenogeneic cell-based vaccine therapy for stage III melanoma: safety, immune-mediated responses and survival benefitsGalina V Seledtsova, Alexey A Shishkov, Erika A Kaschenko, et al.
Current Issues in Molecular Biology|July 23, 2025
Xenogeneic Testicular Cell Vaccination Induces Long-Term Anti-Cancer Immunity in MiceVictor I Seledtsov, Ayana B Dorzhieva, Adas Darinskas, et al.
European Journal of Pharmacology|April 22, 2020
Inhibitory effect of IQ-1S, a selective c-Jun N-terminal kinase (JNK) inhibitor, on phenotypical and cytokine-producing characteristics in human macrophages and T-cellsVictor I Seledtsov, Vladimir V Malashchenko, Maksim E Meniailo, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 30, 2007
Xenovaccinotherapy for colorectal cancerVictor I Seledtsov, Natalya A Niza, Mariya A Felde, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Oncotarget|December 6, 2018
Attaining threshold antibody cytotoxicity for selective tumor cell destruction: an opinion articleVictor I Seledtsov, Galina V Seledtsova
Frontiers in Immunology|April 22, 2017
A Possible Role for Idiotype/Anti-idiotype B-T Cell Interactions in Maintaining Immune MemoryVictor I Seledtsov, Galina V Seledtsova
Expert Review of Clinical Immunology|May 11, 2019
Total threshold cytotoxicity of therapeutic antibodies for selective destruction of pathogenic memory T cells: implications for immunotherapy of autoimmune and allergenic disordersVictor I Seledtsov, Galina V Seledtsova
International Journal of Molecular Sciences|August 28, 2025
Low Antibody Dosing in Cancer Therapy: Targeted Cytotoxicity Combined with Anti-Tumour ImmunostimulationVictor I Seledtsov, Galina V Seledtsova, Adas Darinskas, et al.
Journal of Immunotoxicology|September 8, 2016
Immune responses to polyclonal T-cell vaccination in patients with progressive multiple sclerosisGalina V Seledtsova, Irina P Ivanova, Alexey A Shishkov, et al.
Human Vaccines & Immunotherapeutics|May 8, 2019
Directs effects of granulocyte-macrophage colony stimulating factor (GM-CSF) on adaptive immunogenesisVictor Ivanovich Seledtsov, Vladimir V Malashchenko, Natalja D Gazatova, et al.
European Journal of Dermatology : EJD|March 31, 2016
Xenogeneic cell-based vaccine therapy for stage III melanoma: safety, immune-mediated responses and survival benefitsGalina V Seledtsova, Alexey A Shishkov, Erika A Kaschenko, et al.
Current Issues in Molecular Biology|July 23, 2025
Xenogeneic Testicular Cell Vaccination Induces Long-Term Anti-Cancer Immunity in MiceVictor I Seledtsov, Ayana B Dorzhieva, Adas Darinskas, et al.
European Journal of Pharmacology|April 22, 2020
Inhibitory effect of IQ-1S, a selective c-Jun N-terminal kinase (JNK) inhibitor, on phenotypical and cytokine-producing characteristics in human macrophages and T-cellsVictor I Seledtsov, Vladimir V Malashchenko, Maksim E Meniailo, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|January 30, 2007
Xenovaccinotherapy for colorectal cancerVictor I Seledtsov, Natalya A Niza, Mariya A Felde, et al.
Pageof 2